Skip to Content

Lorbrena FDA Approval History

FDA Approved: Yes (First approved November 2, 2018)
Brand name: Lorbrena
Generic name: lorlatinib
Dosage form: Tablets
Company: Pfizer Inc.
Treatment for: Non-Small Cell Lung Cancer

Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Development Timeline for Lorbrena

DateArticle
Nov  2, 2018Approval FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
Feb 12, 2018U.S., EU and Japan Health Authorities Accept Regulatory Submissions For Review Of Pfizer’s Third-generation ALK Inhibitor Lorlatinib

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.